RESPIT® OROMUCOSAL SPRAY
RESPIT OROMUCOSAL SPRAY
- The latest approach to allergy immunotherapy takes advantage of the mucosal immune system to induce tolerance
- 30 ml multidose bottle of allergenic extract preserved in 50% glycerin, enhancing absorption through mucosa
- 14-21 week supply
- Up to 22 allergens included for each major aerobiological region
- Standardized extracts selected based on geographic region, allergenicity, and cross-reactivity
- Includes dust mites and pollens (grass, tree, and weed) + 2 mold spores
- Daily oral administration is favored by many pet parents over injections
In recent years there has been a shift in human medicine away from administering allergens by subcutaneous immunotherapy (SCIT) in favor of sublingual immunotherapy (SLIT). Many studies have found SLIT to be similarly effective and safer than SCIT.1 One of the primary functions of the mucosal immune system is to develop tolerance of foreign proteins that we (or our pets) ingest. The sublingual and buccal mucosa provide access to the privileged immune system of the oral cavity to induce environmental allergen tolerance.
Several (as of yet unpublished) studies have demonstrated promising results of oral cavity immunotherapy in dogs. At the University of Wisconsin, Doug DeBoer, DVM, DACVD has been working with SLIT for several years. He has demonstrated improvement in clinical lesion scores and medication requirements in house dust mite-sensitive dogs. Results of an open multi-center follow-up study in 100+ multi-sensitized dogs, allergy tested with a variety of methods, have also proven promising, with nearly 60% of dogs responding, including many that had failed to respond to SCIT.
At the University of Florida, Rosanna Marsella, DVM, DACVD has conducted a double-blind, placebo controlled study using customized SLIT allergen mixtures produced by the manufacturer of RESPIT Oromucosal Spray. Of particular note, the study design used atopic dogs with known allergen sensitivity evaluated with an epicutaneous allergen challenge model. The study demonstrated a significant improvement in the treatment group and found the oral spray was safe and well tolerated. Dogs started on a dose of 2 squirts once daily, without an initial up-dosing schedule.
RESPIT Oromucosal Spray combines SkinVet’s practical, patent-pending approach to immunotherapy formulation with the advantages of SLIT into a unique product to better serve your patients and clients.
RESPIT Oromucosal Spray allergenic extract is given by spraying in the oral cavity, between the cheek and gums. Withhold food and water and observe the pet for 30 minutes following dosing.
The suggested dose of RESPIT Oromucosal Spray is based on body weight. Each “squirt” (a full depression of the spray cap) delivers 0.1 ml of the allergen extract. A gradual build-up of the dose, as is recommended for RESPIT Injectable, is usually not necessary. As a precaution, the first dose may be administered under veterinary supervision. For animals with distinctly seasonal signs, beginning therapy 2-3 months prior to the allergy season may prove beneficial. Daily treatment for 3-4 years may result in long-term benefits after discontinuation, based on data in humans.
Before using RESPIT Oromucosal Spray for the first time, fully depress the sprayer 1-2 times over a sink to prime the pump. Twist the nozzle at a right angle to the bottle before use; return to the original position for storage between doses. Refrigeration is recommended. The maintenance dose should stimulate a positive change in the animal’s immune system but not cause exacerbation of clinical signs. Each pet’s ideal dose should be determined during the course of therapy by observing the degree of hypersensitivity they display, if any.
1Sublingual Immunotherapy, World Allergy Organization Position Paper 2009, available at: